Chemically modified synthetic microRNA-205 inhibits the growth of melanoma cells in vitro and in vivo

Molecular Therapy

Volumn 21, Issue 6, 2013, Pages 1204-1211

  Noguchi, Shunsuke ^a   Iwasaki, Junya ^a   Kumazaki, Minami ^a   Mori, Takashi ^a   Maruo, Kohji ^a   Sakai, Hiroki ^a   Yamada, Nami ^a   Shimada, Kazuyuki ^b   Naoe, Tomoki ^b   Kitade, Yukio ^a   Akao, Yukihiro ^a  

^a GIFU UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BENZENE DERIVATIVE; MICRORNA 205; MICRORNA 205 BENZENE PYRIDINE; PROTEIN BCL 2; RIBONUCLEASE; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SYNTHESIS; ENZYME ACTIVITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR XENOGRAFT;

BOVINAE; MUS;

EID: 84878618364     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.70     Document Type: Article

References (31)

1. Miller, AJ and Mihm, MC Jr (2006). Melanoma. N Engl J Med 355: 51-65.
2. Pacheco, I, Buzea, C and Tron, V (2011). Towards new therapeutic approaches for malignant melanoma. Expert Rev Mol Med 13: e33.
3. Russo, AE, Torrisi, E, Bevelacqua, Y, Perrotta, R, Libra, M, McCubrey, JA et al. (2009). Melanoma: molecular pathogenesis and emerging target therapies (Review). Int J Oncol 34: 1481-1489.
4. Eggermont, AM and Robert, C (2011). New drugs in melanoma: It's a whole new world. Eur J Cancer 104: 397-404.
5. Sun, BS, Dong, QZ, Ye, QH, Sun, HJ, Jia, HL, Zhu, XQ et al. (2008). Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Hepatology 48: 1834-1842.
6. Cannell, IG, Kong, YW and Bushell, M (2008). How do microRNAs regulate gene expression? Biochem Soc Trans 36(Pt 6): 1224-1231.
7. Bartel, DP (2009). MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233.
8. Chiang, HR, Schoenfeld, LW, Ruby, JG, Auyeung, VC, Spies, N, Baek, D et al. (2010). Mammalian microRNAs: experimental evaluation of novel and previously annotated genes. Genes Dev 24: 992-1009.
9. Harfe, BD (2005). MicroRNAs in vertebrate development. Curr Opin Genet Dev 15: 410-415.
10. Lynam-Lennon, N, Maher, SG and Reynolds, JV (2009). The roles of microRNA in cancer and apoptosis. Biol Rev Camb Philos Soc 84: 55-71.
11. Zhang, J, Jima, DD, Jacobs, C, Fischer, R, Gottwein, E, Huang, G et al. (2009). Patterns of microRNA expression characterize stages of human B-cell differentiation. Blood 113: 4586-4594.
12. Kaddar, T, Rouault, JP, Chien, WW, Chebel, A, Gadoux, M, Salles, G et al. (2009). Two new miR-16 targets: caprin-1 and HMGA1, proteins implicated in cell proliferation. Biol Cell 101: 511-524.
13. Kunz, M (2013). MicroRNAs in Melanoma Biology. Adv Exp Med Biol 774: 103-120.
14. Felli, N, Felicetti, F, Lustri, AM, Errico, MC, Bottero, L, Cannistraci, A et al. (2013). miR-126&126* restored expressions play a tumor suppressor role by directly regulating ADAM9 and MMP7 in melanoma. PLoS ONE 8: e56824.
15. Dynoodt, P, Speeckaert, R, De Wever, O, Chevolet, I, Brochez, L, Lambert, J et al. (2013). miR-145 overexpression suppresses the migration and invasion of metastatic melanoma cells. Int J Oncol 42: 1443-1451.
16. Cho, WC (2012). Great potential of miRNAs as predictive and prognostic markers for cancer. Expert Rev Mol Diagn 12: 315-318.
17. Cho, WC (2012). MicroRNAs as therapeutic targets and their potential applications in cancer therapy. Expert Opin Ther Targets 16: 747-759.
18. Catto, JW, Alcaraz, A, Bjartell, AS, De Vere White, R, Evans, C P, Fussel, S et al. (2011). MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol 59: 671-681.
19. Xu, Y, Brenn, T, Brown, ER, Doherty, V and Melton, DW (2012). Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors. Br J Cancer 106: 553-561.
20. Noguchi, S, Mori, T, Hoshino, Y, Yamada, N, Maruo, K and Akao, Y (2012). MicroRNAs as tumour suppressors in canine and human melanoma cells and as a prognostic factor in canine melanomas. Vet Comp Oncol (in press).
21. Liu, S, Tetzlaff, MT, Liu, A, Liegl-Atzwanger, B, Guo, J and Xu, X (2012). Loss of microRNA-205 expression is associated with melanoma progression. Lab Invest 92: 1084-1096.
22. Dar, AA, Majid, S, de Semir, D, Nosrati, M, Bezrookove, V and Kashani-Sabet, M (2011). miRNA-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1 protein. J Biol Chem 286: 16606-16614.
23. Cho, WC (2010). MicroRNAs in cancer-from research to therapy. Biochim Biophys Acta 1805: 209-217.
24. Ueno, Y, Watanabe, Y, Shibata, A, Yoshikawa, K, Takano, T, Kohara, M et al. (2009). Synthesis of nuclease-resistant siRNAs possessing universal overhangs. Bioorg Med Chem 17: 1974-1981.
25. Noguchi, S, Mori, T, Hoshino, Y, Maruo, K, Yamada, N, Kitade, Y et al. (2011). MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells. Cancer Lett 307: 211-220.
26. Akao, Y, Nakagawa, Y, Hirata, I, Iio, A, Itoh, T, Kojima, K et al. (2010). Role of anti-oncomirs miR-143 and-145 in human colorectal tumors. Cancer Gene Ther 17: 398-408.
27. Wu, H, Zhu, S and Mo, YY (2009). Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res 19: 439-448.
28. Engelmann, D and Pützer, BM (2012). The dark side of E2F1: in transit beyond apoptosis. Cancer Res 72: 571-575.
29. Alla, V, Engelmann, D, Niemetz, A, Pahnke, J, Schmidt, A, Kunz, M et al. (2010). E2F1 in melanoma progression and metastasis. J Natl Cancer Inst 102: 127-133.
30. Gregory, PA, Bert, AG, Paterson, EL, Barry, SC, Tsykin, A, Farshid, G et al. (2008). The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10: 593-601.
31. Tang, Y, Simoneau, AR, Liao, WX, Yi, G, Hope, C, Liu, F et al. (2009). WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells. Mol Cancer Ther 8: 458-468.